Matthew Galsky, M.D.
Hoosier Cancer Research Network
4
0
2
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (4)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Andrea B Apolo, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jian Huang, MD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Yair Lotan, MD
University of Texas Southwestern Medical Center
Shared therapeutic areas:
Dean Bajorin, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jeremie Calais
UCLA / Jonsson Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Jitendra Amlani, MD
Urocare Hospital
Shared therapeutic areas:
Jeffrey Skolnik, MD
Inovio Pharmaceuticals
Shared therapeutic areas:
Anish Thomas, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (4)
Showing 4 of 4 trials
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
All 4 trials loaded